Krankenhaus Der Barmherzigen Brueder

Running trials

• Active, not recruiting

  MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma

  2023-505436-35-00· Phase 3· Source

• Recruiting

  MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  NCT04111978· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ovarian cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  CIRCULATE

  NCT04089631· Phase 3· Source